Episode

Episode 183 - Matt Erick - CCO Biocon Biologics

Podcast
The BioHub - by Avetix
Published
Jun 2, 2026
Duration seconds
1509
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-183---Matt-Erick---CCO-Biocon-Biologics-e3k856f
Audio
https://anchor.fm/s/f0076084/podcast/play/120902287/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-5-2%2F425370892-44100-2-b24c10d4b21db.mp3
JSON
/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-183-matt-erick-cco-biocon-biologics
Markdown
/podcast/the-biohub-by-avetix-7252289/episode-183-matt-erick-cco-biocon-biologics.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-183-matt-erick-cco-biocon-biologics/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-183-matt-erick-cco-biocon-biologics.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Matt Erick, Chief Commercial Officer for Advanced Markets at Biocon Biologics, joins Max on The BioHub Podcast. With more than two decades of experience across pharma, biologics, distribution, and healthcare services, Matt has helped shape commercial strategy across some of the industry's most complex and competitive markets. In this conversation, we discuss Biocon's expansion into the U.S., the integration of its generics and biosimilars businesses, the evolution of the biosimilars market, and the role these medicines play in improving patient access worldwide. We also explore the challenges of navigating policy and regulatory change, building long-term commercial strategies, and driving growth in a challenging market environment.